Verastem, Inc., a biopharmaceutical company, focuses on discovering and developing proprietary small molecule drugs targeting cancer stem cells (CSCs) with companion diagnostics. Its programs target the Focal Adhesion Kinase (FAK) and the PI3K/mTOR signaling pathways. The companys lead FAK inhibitor, VS-6063, is in Phase I/Ib testing in ovarian cancer, as well as developing for the treatment of mesothelioma and breast cancer. It is also developing FAK inhibitor VS-4718 and PI3K/mTOR inhibitor VS-5584 in patients with advanced cancers. The companys product candidates target CSCs that have been implicated in aggressive cancers, metastasis, and chemotherapeutic resistance. Verastem, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
March 3, 2023
RegMed Investors’ (RMi) closing bell: sector gets a push pull
February 10, 2023
RegMed Investors’ (RMi) closing bell: sector shot down by inflationary “objects”
February 1, 2023
RegMed Investors’ (RMi) closing bell: We waited for Jerome – 25-basis points, Godot never really had a day in the limelight
January 27, 2023
RegMed Investors’ (RMi) closing bell: the tide came without a full moon effect
January 26, 2023
RegMed Investors’ (RMi) closing bell: investing in the soft sand at low tide
January 25, 2023
RegMed Investors’ (RMi) closing bell: sector finishes down yet, made strides late in session
January 25, 2023
RegMed Investors’ (RMi) pre-open: share pricing is all over the map as some gains reverse
January 24, 2023
Verastem Oncology (VSTM) $60 M Private Placement Offering of Series B Convertible Preferred Stock
January 12, 2023
RegMed Investors’ (RMi) closing bell: cell/gene therapy sector appreciated in recent sessions as CPI report confirmed a weakening inflation trend
35 companies, 1 interpreter!
Insight, foresight and recommendation
Verastem (VSTM) -- Opened 2018 at $3.21, started February at $3.55 and March at $3.05 with a high of $3.24 on 3/6 - neeeds news which always stimulates volume and pricing offsetting complacency in share pricing ...
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors